Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
2.530
+0.050 (2.02%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Lisata Therapeutics Revenue
In the year 2024, Lisata Therapeutics had annual revenue of $1.00M. Lisata Therapeutics had revenue of $1.00M in the quarter ending December 31, 2024.
Revenue (ttm)
$1.00M
Revenue Growth
n/a
P/S Ratio
21.07
Revenue / Employee
$38,462
Employees
26
Market Cap
21.27M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
LSTA News
- 13 days ago - Lisata Therapeutics Announces Research License with Catalent - GlobeNewsWire
- 7 weeks ago - Lisata Therapeutics to Present at the Investival Showcase USA - GlobeNewsWire
- 7 weeks ago - Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development - GlobeNewsWire
- 2 months ago - Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025 - GlobeNewsWire
- 3 months ago - Lisata Therapeutics to Present at the 2025 Sequire Investor Summit - GlobeNewsWire
- 4 months ago - Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial - GlobeNewsWire